EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study

Sarah Moen, Pieter H A Wisse, Fleur Marijnissen, Hannah Raab, Iris Lansdorp-Vogelaar, Jeroen M Jansen, Merel M Tielemans, I Leeuwenburgh, Leonieke M M Wolters, Lieke Hol, Pieter C J Ter Borg, Frank C Bekkering und 6 weitere

Endoscopy · 01.02.2026 · 58 (02) · 174-183

DOI: 10.1055/a-2650-0664 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endoscopy, erschienen am 01.02.2026. Verfasst von Sarah Moen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Colonic Polyps, Colonoscopy, Colorectal Neoplasms, Feces. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In most colonoscopies performed for bowel symptoms, no significant lesions are found. To decrease the number of unnecessary colonoscopies, we evaluated the performance of two-sample fecal immunochemical testing (FIT) in ruling out significant lesions. Symptomatic patients referred for colonoscopy were instructed to perform two FITs from separate bowel movements prior to colonoscopy. Colonoscopy and pathology data were collected. Two-sample FIT was considered positive when FIT1 and/or FIT2 results were positive. Sensitivity and negative predictive value (NPV) for advanced neoplasia, advanced serrated polyps, and colitis were determined at different cutoff values. 949 patients (median age 61 years, 50.6% male) from 10 centers were included. The highest NPVs and sensitivities were reached with two-sample FIT using the lowest limit of fecal hemoglobin detection (>1.7 µg Hb/g). For advanced neoplasia and CRC, this resulted in NPVs of 95.6% and 99.7%, and sensitivities of 71.7% and 93.9%, respectively. Sensitivity for advanced neoplasia was higher (84.6%) in patients with the alarm symptoms of rectal blood loss and/or anemia. NPV and sensitivity for inflammatory bowel disease were 99.3% and 83.3%, respectively. Concordant negative results were found for 675 patients (71.1%). Despite a high NPV, two-sample FIT still missed 28.3% of advanced neoplasia. Therefore, two-sample FIT may play a role in determining the need for colonoscopy in symptomatic patients, but it misses too many lesions to be used as the sole determinant for averting colonoscopy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic PolypsColonoscopyColorectal NeoplasmsFecesOccult BloodAdultAgedFemaleHumansMaleMiddle AgedColitisEarly Detection of CancerHemoglobinsImmunochemistryInflammatory Bowel DiseasesPredictive Value of TestsProspective StudiesSensitivity and SpecificityUnnecessary Procedures

Substanzen

Hemoglobins

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Department of Gastroenterology and Hepatology, PoliDirect Independent Treatment Centers, Amsterdam, Netherlands.
  • Department of Gastroenterology and Hepatology, Bravis Hospital, Roosendaal, Netherlands.
  • Department of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands.
  • Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, Netherlands.

ORCID-Profile: Manon C W Spaander

Zitieren

APA

Moen, S., Wisse, P. H. A., Marijnissen, F., Raab, H., Lansdorp-Vogelaar, I., Jansen, J. M., Tielemans, M. M., Leeuwenburgh, I., Wolters, L. M. M., Hol, L., Ter Borg, P. C. J., Bekkering, F. C., Mulder, S., Schot, I., Frasa, M., Thelen, M., van Vuuren, A. J., & Spaander, M. C. W. (2026). Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study. Endoscopy, 58(02), 174-183. https://doi.org/10.1055/a-2650-0664

Vancouver

Moen S, Wisse PHA, Marijnissen F, Raab H, Lansdorp-Vogelaar I, Jansen JM, et al. Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study. Endoscopy. 2026;58(02):174-183. doi:10.1055/a-2650-0664

BibTeX
@article{Moen2026,
  author = {Moen, Sarah and Wisse, Pieter H A and Marijnissen, Fleur and Raab, Hannah and Lansdorp-Vogelaar, Iris and Jansen, Jeroen M and Tielemans, Merel M and Leeuwenburgh, I and Wolters, Leonieke M M and Hol, Lieke and Ter Borg, Pieter C J and Bekkering, Frank C and Mulder, Sanna and Schot, Ingrid and Frasa, Marieke and Thelen, Marc and van Vuuren, Anneke J and Spaander, Manon C W},
  title = {Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {02},
  pages = {174--183},
  doi = {10.1055/a-2650-0664}
}
Kostenlos starten →